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Background: Glioblastoma multiforme (GBM) is the most aggressive type of glioma and carries the poorest
chances of survival. There is therefore an urgent need to understand the mechanisms of glioma tumorigenesis and
develop or improve therapeutics. The aim of this study was to assess the possible prognostic value of
cyclin-dependent kinase 6 (CDK6) and the effects of microRNA-495 (miR-495) manipulation on CDK6 expression and
cell survival in glioma cells.
Methods: Analyses of clinical specimens from GBM patients were used. Expression of CDK6 was analyzed by
real-time polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemistry. Expression of CDK6 was
also analyzed after over-expression of miR-495 in T98 cells; both cell proliferation and RB phosphorylation were
examined. Cell proliferation, cell cycle distribution, and RB phosphorylation were also examined after knockdown of
CDK6 in U87-MG and T98 cells.
Results: Analyses of clinical specimens from GBM patients identified that CDK6 is significantly expressed in gliomas.
CDK6 antigen expression was higher in tumor cores and margins than in adjacent normal brain tissues, and higher
levels of CDK6 expression in the tumor margin correlated with decreased survival. Over-expression of miR-495 in
T98 cells downregulated the expression of CDK6 and inhibited retinoblastoma phosphorylation, and knockdown of
CDK6 in U87-MG and T98 cells by siRNAs resulted in cell cycle arrest at the G1/S transition and inhibition of cell
proliferation.
Conclusions: This study revealed miR-495 is down-regulated in glioma tissues. Furthermore, miR-495 regulated
CDK6 expression and involved in glioma cell growth inhibition, which indicated the possible role of miR-495 in
tumor progression.
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Malignant gliomas, the most common primary brain
malignant tumor, are aggressive, highly invasive, and
neurologically destructive human cancers. Glioblastoma
multiforme (GBM), the most aggressive manifestation of
gliomas, typically affects adults between 45 and 60 years of
age. Despite advances in surgical techniques, radiotherapy,
and chemotherapy, the prognoses of patients with GBMs* Correspondence: anray5319@cgmh.org.tw
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reproduction in any medium, provided the orremain dismal [1], largely because of recurrences from
extensions of tumor cells to adjacent regions.
Establishing the molecular basis of the tumorigenesis
of malignant gliomas is crucial to improving current ther-
apies and developing new ones. It has been suggested that
gene expression profiles from glioma specimens might
predict patient outcome more accurately than pathological
criteria [2,3]. In particular, the cell cycle regulator enzyme
cyclin-dependent kinase 6 (CDK6) is over-expressed in
GBM [4,5], although not all the over-expression can be
explained by genomic amplification, suggesting that other
gene regulatory mechanisms might be involved [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chen et al. World Journal of Surgical Oncology 2013, 11:87 Page 2 of 8
http://www.wjso.com/content/11/1/87MicroRNAs (miRs) are small (18 to 22 nucleotides),
non-coding RNAs with post-transcriptional gene silencing
activity [6,7] that regulate gene expression by associating
with the 30-untranslated region (30-UTR) of genes and
inhibiting protein translation [8]. miRs can also destabilize
and mediate the degradation of RNA transcripts [9]. In
addition to their role in normal development, miRs are
also associated with carcinogenesis [10,11]. For example,
miR-21 is over-expressed in glioblastoma, whereas its
inhibition inhibits glioblastoma growth in vitro and in vivo
[12]. In contrast, some miRs act as tumor suppressors:
miR-34 functions as a p53-dependent tumor suppressor in
neuroblastoma [13], and miR-124 inhibits CDK6 and thus
reduces tumor proliferation in medulloblastoma [14].
In the present study, we reveal that miR-495 is signifi-
cantly decreased in GBM samples, and sequence analysis
using TargetScan 6.2 identified the 30-UTR of CDK6 as a
potential target of miR-495. The present study also demon-
strates that expression of CDK6 antigen, particularly in the
tumor margins, is prognostic of poor patient survival.
Furthermore, CDK6 is downregulated by over-expression
of miR-495 in GBM cells, suggesting that miR-495 might
play an important role in malignant glioma tumorigenesis.
Methods
Patient population
The patient population consisted of 20 adults (16 male,
4 female; mean age at sampling = 56.5 yrs). Written,
informed consent was obtained from all patients, and the
study was approved by, and performed according to, the
guidelines of the Institutional Review Board of Chang Gung
Memorial Hospital (Approval #94-182 and #98-0341B).
GBM was verified in histological specimens between Feb
2004 and July 2009 by a neuropathologist according to
World Health Organization criteria. All 20 cases were
classified as grade 4, with 18 cases of GBM and 2 cases of
glioblastoma with oligodendroglioma.
Region-specific specimen collection
Deep-seated tumors were removed using an intraoperative
navigation system (BrainLAB, Feldkirchen, Germany) that
minimized invasiveness and maximized patient safety and
accurate tumor resection. Brain tissue samples were
collected from the resection zone, categorized as peripheral
normal brain, tumor marginal tissue or tumor core, and
stored in liquid nitrogen as described previously [15].
Real-time polymerase chain reaction
The following primers and probe for CDK6 were used:
forward: 50-TGCACAGTGTCACGAACAGA-30; reverse:
50-ACCTCGGAGAAGCTGAAACA-30 (Mission Biotech,
Taipei, Taiwan); probe: 50-CATATTGCTTCAATGCTT
CAGCTCCACCTG-30 (Applied Biosystems, Carlsbad,
CA, USA). RT-PCR was performed as follows: 50°C for2 min; 95°C for 15 min; 40 cycles of 95°C for 15 s and
60°C for 1 min. Experiments were performed in triplicate.
Gene expression levels were calculated by the ΔΔCt
method and normalized against the RPL35A control.
Expression of hsa-miR-495 was analyzed using specific
primers and TaqMan probe according to the manufac-
turer’s protocol (Applied Biosystems) and normalized in
each sample against expression of the RNU44 gene.
Immunoblotting
Brain tumor samples were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed on ice in
chilled T-PER tissue protein extraction reagent (Pierce,
Rockford, IL, USA) containing a protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO, USA). Lysates were cleared
by centrifugation, and total protein concentrations were de-
termined by Bradford assay (Bio-Rad, Hercules, CA, USA).
Protein samples (30 μg/lane) were separated on 12% poly-
acrylamide gels by sodium dodecyl sulfate/polyacrylamide
gel electrophoresis and transferred to polyvinylidene
difluoride membranes (Millipore, Billerica, MA, USA).
Blots were blocked overnight in 20 mM Tris–HCl,
150 mM NaCl, 0.1% Tween-20, 0.5 μM EDTA (pH 7.4)
containing 5% non-fat dry milk, incubated for 2 h with
anti-human CDK6 antibodies (1:1,000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or anti-human
phosphorylated retinoblastoma (pRB) antibodies (1:500;
Santa Cruz Biotechnology), and then incubated with
horseradish peroxidase-conjugated goat anti-mouse or anti-
rabbit IgG (1:10,000; PerkinElmer, Waltham, MA, USA)
for 1 h. Specific labeling was visualized using the Western
Lightning Detection kit (PerkinElmer) according to the
manufacturer’s instructions.
Immunohistochemistry
Tissue sections from peripheral, marginal, and tumor
core regions were deparaffinized, treated with 3% H2O2 for
10 min at room temperature, and then microwaved in 0.01
M citrate buffer (pH 6.0) to retrieve antigenicity. The
sections were blocked with 1% bovine serum albumin in
PBS for 20 min at room temperature and incubated
overnight with a mouse anti-human CDK6 monoclonal
antibody (Santa Cruz Biotechnology) diluted 1:100 in the
blocking buffer. Samples were washed four times with PBS
and incubated with goat anti-mouse IgG (PerkinElmer).
Immunocomplexes were visualized by an LSAB 2 HRP kit
(Dako, Carpinteria, CA, USA) using 3,30-diaminobenzidine
tetrachloride as a substrate. Sections were counterstained
lightly with hematoxylin, dehydrated with a graded alcohol
series, cleared with xylene, and mounted with coverslips.
Cell lines
Two malignant glioma cell lines (T98 and U87-MG)
were purchased from American Type Culture Collection.
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medium (MEM, Life Technologies, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum
(Life Technologies), 1% non-essential amino acids, and 1%
penicillin and streptomycin (Life Technologies).
siRNA transfection
The siRNAs for CDK6 (43900824 ID: S51 and S53) and
control siRNA#1 were purchased from Ambion (Austin,
TX, USA). T98 and U87-MG cells were transfected with
siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol.
miRNA transfection
Over-expression of miR-495 was accomplished using
BLOCK-iT™ Pol II miR RNAi Expression Vector Kits
(Invitrogen) to generate an expression clone containing
a double-stranded oligo encoding a pre-miR-495 se-
quence. The constructs were transfected into T98 cells
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol.
Cell cycle analysis
T98 and/or U87-MG cells were harvested from medium
following siRNA treatments. Cells were fixed in 70%
ethanol and stored at −20°C until use. After thawing and
equilibrating to room temperature, the cells were
resuspended in PBS containing 0.5% Triton X-100 and
0.05% RNase, stained with 50 μg/mL propidium iodide
(Sigma), and maintained at 4°C for 30 min. Cell cycles
were analyzed by flow cytometry using a FACS-Calibur
incorporating Cell Quest software (BD Biosciences,
Mountain View, CA, USA) and WinMDI 2.8 software
(Salk Institute for Biological Studies, La Jolla, CA, USA).
MTT assay
A total of 1 × 104 T98 or U87-MG cells were cultured
in 96-well tissue-culture plates overnight, and then
treated with siRNA or miRNA as described above. After 1
to 5 days, glioma cells were incubated for three hours
in 100 μL of 0.1-mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma). Cells
were resuspended in 200 μL isopropanol (to dissolve
the formazan), and the optical density of the solution
was determined using a spectrometer at an incident
wavelength of 570 nm. Cell viabilities in experimental
wells were expressed as a percentage of the viability in
the control well.
Statistical analyses
Wilcoxon signed-rank tests were used to compare the
levels of CDK6 and miR-495 expression between brain
tumor core, margin, and normal peripheral tissues.
Survival curves were estimated using the Kaplan-Meiermethod, with progression-free survival defined as the
period from initial diagnosis to tumor progression
(or the last follow-up). Logrank tests were used to evaluate
the association between expression levels in different
tumor sections and patient survival; GBM cases were
categorized as having high or low expression levels
relative to the median values. All analyses were performed
using SAS statistical software version 9.1.3 (SAS Institute
Inc., Cary, NC, USA). All P values were two-sided, with
0.05 being considered significant.
Results
Expression of CDK6 in human glioma tissues
In 20 sets of tissue samples collected from different brain
regions, expression of the CDK6 gene was upregulated
significantly in tumor core samples (P = 0.0042) relative to
peripheral normal brain, although expression decreased
progressively in samples taken more distally (Figure 1e).
Immunoblotting confirmed increased CDK6 protein ex-
pression in malignant gliomas consistent with the elevated
transcript levels (Figure 1f), and immunohistochemistry
verified the graded distribution of the protein in the
tumors (Figure 1a–d).
Correlation of CDK6 expression with survival rates
Kaplan-Meier survival plots showed a relationship between
CDK6 expression and survival rates in GBM patients.
However, although higher CDK6 transcript levels in tumor
cores indicated poorer survival, the correlation was not
statistically significant (Figure 2; P = 0.0529). In contrast,
patients with higher levels of CDK6 transcripts in the tumor
margin had significantly poorer prognoses than those with
submedian levels of CDK6 (Figure 2; P = 0.0279).
Knockdown of CDK6 inhibits cell proliferation and arrests
glioma cells
Knockdown of CDK6 reduced expression of both CDK6
transcripts (Figure 3a) and protein (Figure 3b). Further-
more, levels of pRB (pSer 795), a known target of CDK6,
were also reduced in response to CDK6 knockdown
(Figure 3b). Furthermore, knockdown of CDK6 inhibited
proliferation of T98 and U87-MG cells (Figure 3d). Cell
cycle analyses by flow cytometry showed that T98 and
U87-MG cells transfected with siCDK6 had a higher
percentage of cells in G0/G1 phase than negative control
cells (Figure 3c). Concomitantly, the percentage of cells in
S phase and in G2/M phase was reduced, suggesting that
silencing CDK6 inhibits growth by arresting the cell cycle
at the G1/S transition.
miR-495 is downregulated in GBM tissues
RT-PCR analysis was used to measure expression of
mature miR-495 sequences in the three defined regions
from patients with GBM. Expression of miR-495 was
Figure 1 CDK6 expression in surgically defined regions. Immunohistochemical staining of normal peripheral tissues (a,c) and glioma tissues
(b,d); (e) RT-PCR analysis of CDK6 expression in samples from different regions of gliomas; (f) CDK6 protein expression detected by
immunoblotting. N: Normal peripheral tissue; T: Tumor tissue.
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relative to normal peripheral brain tissue, although the
downregulation was more pronounced in the tumor
core (Figure 4a; P = 0.0004).
miR-495 inhibits CDK6 expression, pRB levels, and inhibits
growth of GBM cells
Transfection of miR-495 into T98 cells reduced expression
of CDK6 protein (Figure 4c). Furthermore, pRB levels
were also reduced in response to miR-495 transfection
(Figure 4c). MTT analyses confirmed that over-expression
of miR-495 inhibited the growth of T98 cells (Figure 4d).
Discussion
Establishing the factors responsible for the development,
proliferation, metastasis, and recurrence of brain tumors
could help identify potential diagnostic markers or
targets for new therapeutic regimens. In the present
study, we report the potential role of CDK6 and its pos-
sible regulatory mechanism in glioblastoma. CDK6 is a
member of a family of serine/threonine kinases involved
in the control of cell cycle progression, interacting with
cyclin D to phosphorylate the retinoblastoma protein
during the G1/S transition [16]. Alterations of CDK6
expression have been reported in several tumor types,
including T-cell lymphoma [17], medulloblastoma [18],neuroblastoma [19], and gastric cancer [20]. Elevated
expression of CDK6 protein has also been reported in
GBM, and CDK6 is thought to be associated with astro-
cytic tumorigenesis [4,5]. The present study indicates
that CDK6 is expressed both transcriptionally and trans-
lationally at higher levels in GBM tissues. Furthermore,
CDK6 is expressed more abundantly in the tumor core
than in marginal or peripheral regions. Thus, CDK6
expression correlates with the density of malignant cells
in tumor-affected regions, and may be involved in the
microenvironments of scattered glioma cells.
Analysis of survival data from patients with GBM
reveals that, although elevated expression of CDK6 RNA
in the tumor cores trended toward poor survivability,
the results were not statistically significant. In contrast,
the correlation between CDK6 expression in tumor
marginal regions and poor survival was significant, pos-
sibly because tumor recurrence usually originates in the
residual tumor margin after tumor resection. Thus, even
tissues surrounding a tumor can provide valuable prog-
nostic indicators for patient survival. Since only deep
seated glioma would be resected under the help of an
intraoperative navigation system, collection of sample
sets including tumor core, margin, and periphery is
strictly limited. However, these restricted samples still
provide statistically important information, which indicate
Figure 3 Effects of CDK6 knockdown by siRNAs. (a) RT-PCR analysis of CDK6 expression in CDK6-knocked down cells; (b) Immunoblot analysis
of CDK6 and pRB protein; (c) DNA flow cytometry on cell cycle stage distribution in T98 cells harvested 48 h after transfection; (d) Viability of
CDK6-knocked down cells.
Figure 2 Kaplan-Meier survival curves of 20 GBM patients. Survival time is defined as the time from diagnosis to progression or last known
follow-up, where circles represent censored values. Solid lines represent low levels of CDK6 expression (i.e., less than the median value); dotted
lines indicate cases with CDK6 expression equal to or above the median value.
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Figure 4 Expression of miR-495 in glioma cells and tissues. (a) miR-495 expression in tissue samples from defined regions of glioma patients;
(b) miR-495 expression in T98 cells transfected with miR-495; (c) Immunoblot analyses of CDK6 and pRB protein expression in T98 cells over-
expressing miR-495; (d) MTT assay of effects of miR-495 over-expression in T98 cells.
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correlate with poor prognosis.
In GBM, CDK6 is amplified genomically in some, but
not all, of the tumors that over-express CDK6 protein,
suggesting that other regulatory mechanisms might control
CDK6 expression in GBM tumors [5]. miRNAs are small
non-coding RNA molecules that regulate protein expres-
sion by cleaving or repressing the translation of target
mRNAs. Aberrant expression of miRNAs in cancer is well
documented, e.g., in chronic lymphocytic leukemia [21],
breast carcinoma [22,23], lung cancer [24], papillary
thyroid carcinoma [25], colon carcinoma [26], pancreatic
tumors [27,28], and primary glioblastoma [29,30]. These
miRNAs regulate the expression of signaling molecules
such as cytokines, growth factors, transcription factors,
and pro- and anti-apoptotic genes. miRNAs also act as
regulators of many neuronal functions [31]. Specifically,
miR-125b regulates the proliferation of U251 glioma stem
cells through the cell cycle-regulated proteins CDK6 and
CDC25A [32]. Similarly, miR-124 and miR-137 inhibit
proliferation of GBM cells and induce differentiation of
brain tumor stem cells by inhibiting CDK6 [33].
miR-495 regulates the expression of brain-derived
neurotrophic factor in brain [34] and hepatocyte nuclearfactor 6 and Onecut 2 in developing liver and pancreas
[35]. miR-495 also inhibits the migration and invasion of
human gastric cancer cells by directly interacting with
PRL-3 [36]. In this study, we found that miR-495 was
expressed at low levels in malignant glioma tumor tis-
sues, therefore suggesting that its up-regulation can lead
to the growth inhibition of glioma cells. Furthermore,
TargetScan 6.2 predicts six potential target sites of miR-
495 in the 30-UTR of CDK6. The present work confirms
miR-495 as a regulator of CDK6 expression. miR-495
was expressed at lower levels in malignant glioma
tumor tissues than in normal peripheral tissues, and its
upregulation inhibited the growth of glioma cells in vitro.
Further studies will be required to determine the precise
mechanism by which over-expression of miR-495 decreases
CDK6 expression and inhibits glioma cell proliferation.
Given that aberrantly expressed miRNAs can play key
roles in the development of human cancers, recent studies
increasingly emphasize the potential therapeutic applica-
tions of these molecules [37-39]. Both loss and gain of
miRNA function can result in cancer development through
the upregulation and silencing, respectively, of particular
target genes. Correcting these miRNA dysregulations
by either miRNA antagonists or miRNA mimics might
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with key pathways involved in cancer development.Conclusions
In summary, high levels of expression of the cell cycle
regulatory protein CDK6 are indicative of a poor prog-
nosis in patients with GBM, especially when expressed
in tumor margins. In contrast, expression of miR-495
(a putative regulator of CDK6 expression) is low in glioma
tumor tissues, whereas its over-expression appears to
block or delay the G1/S transition of the cell cycle by
downregulating CDK6, thus inhibiting proliferation of
malignant glioma cells. In the present study, we report the
significance of analyzing tissues adjacent to glioblastoma
tumors, and the correlation of CDK6 levels and better
survival. Since tumor adjacent tissues of glioblastomas are
the therapeutic target area of post-operational treatment,
the biological nature of tumor adjacent regions may be
the key factor that affects the prognosis of glioblastoma.
The efforts on investigating the biological nature of this
area may provide important information for therapeutic
strategy selection and development.
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